NEWS analyste us vise 73 dollars!

73$ ! Je signe où ??? 🥳🥳

Suffit de regarder le graphe pour voir sur quel niveau d'enfumage, on est ...

: (

Message complété le 19/12/2019 16:36:36 par son auteur.

Encore un message du roi des infos qui disparaissent...

: (

demain grosse journée

Nomura Reaffirms "Buy" Rating for Cellectis (NASDAQ:CLLS)

Monday, December 16th, 2019

Gayle Cristol

Cellectis (NASDAQ:CLLS)'s stock had its "buy" rating restated by investment analysts at Nomura in a research note issued on Monday, AnalystRatings.com reports. They presently have a $73.00 price objective on the biotechnology company's stock. Nomura's price target would suggest a potential upside of 357.68% from the stock's current price.

CLLS has been the topic of several other research reports. BidaskClub raised Cellectis from a "hold" rating to a "buy" rating in a report on Thursday, December 5th. Zacks Investment Research raised Cellectis from a "hold" rating to a "buy" rating and set a $15.00 price objective on the stock in a report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. The company presently has an average rating of "Buy" and a consensus target price of $36.17.

Cellectis stock opened at $15.95 on Monday. Cellectis has a 1-year low of $9.50 and a 1-year high of $20.84. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.99 and a quick ratio of 7.93. The stock has a market cap of $677.08 million, a PE ratio of -8.26 and a beta of 1.82. The stock's fifty day moving average is $13.35 and its two-hundred day moving average is $13.43.

Several hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. grew its holdings in shares of Cellectis by 32.6% during the third quarter. Point72 Asset Management L.P. now owns 189,000 shares of the biotechnology company's stock worth $1,966,000 after purchasing an additional 46,500 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Cellectis by 8.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,314,295 shares of the biotechnology company's stock worth $13,669,000 after purchasing an additional 104,276 shares during the last quarter. Nikko Asset Management Americas Inc. grew its holdings in shares of Cellectis by 7.3% during the third quarter. Nikko Asset Management Americas Inc. now owns 1,314,295 shares of the biotechnology company's stock worth $13,669,000 after buying an additional 89,961 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Cellectis by 22.1% during the third quarter. Envestnet Asset Management Inc. now owns 50,228 shares of the biotechnology company's stock worth $522,000 after buying an additional 9,088 shares during the last quarter. Finally, OneAscent Financial Services LLC purchased a new position in shares of Cellectis during the second quarter worth about $257,000. 30.97% of the stock is currently owned by institutional investors.